Élucidation et identification des différents interacteurs impliqués dans le mécanisme de régulation du LDLR par la protéine PCSK9

Élucidation et identification des différents interacteurs impliqués dans le mécanisme de régulation du LDLR par la protéine PCSK9

Résumé : Les maladies cardiovasculaires représentent la principale cause de mortalité mondiale, soit le tiers des décès annuels selon l’Organisation mondiale de la Santé. L’hypercholestérolémie, caractérisée par une élévation des niveaux plasmatiques de lipoprotéines de faible densité (LDL), est l’u...

Full description

Bibliographic Details
Main Author:	Ly, Kévin
Other Authors:	Day, Robert
Language:	French English
Published:	Université de Sherbrooke 2016
Subjects:	PCSK9 LDLR cholestérol Annexin A2 Glypican-3 Cholesterol
Online Access:	http://hdl.handle.net/11143/9786

Similar Items

The association of LDLR and PCSK9 variants with LDL-c levels in a black South African population in epidemiological transition / Tertia van Zyl
by: Van Zyl, Tertia
Published: (2016)

The association of LDLR and PCSK9 variants with LDL-c levels in a black South African population in epidemiological transition / Tertia van Zyl
by: Van Zyl, Tertia
Published: (2016)

The Functional Characterization of PCSK9's Binding Interactions with LDL and the LDL Receptor
by: Matyas, Angela
Published: (2020)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
by: Aikaterini Arida, et al.
Published: (2021-10-01)

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro
by: Li Li, et al.
Published: (2018-09-01)

PCSK9 - A New and Potent Approach to Lowering Cholesterol
by: Thomas F. Whayne Jr.
Published: (2013-05-01)

Comparing expression and activity of PCSK9 in SPRET/EiJ and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol
by: Francine Sirois, et al.
Published: (2017-03-01)

c-IAP1 Binds and Processes PCSK9 Protein: Linking the c-IAP1 in a TNF-α Pathway to PCSK9-Mediated LDLR Degradation Pathway
by: David Hornby, et al.
Published: (2012-10-01)

Prenylated Flavonoid Glycosides with PCSK9 mRNA Expression Inhibitory Activity from the Aerial Parts of <i>Epimedium koreanum</i>
by: Eeray Kim, et al.
Published: (2021-06-01)

PCSK9 and LDL-C: The Role of Exercise
by: Jaeho Jin, et al.
Published: (2020-11-01)

Caracterização funcional in vitro de variantes no gene PCSK9 identificadas em pacientes com Hipercolesterolemia Familial
by: Los, Bruna
Published: (2019)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

Asociation of PCSK9 with Low Density Lipoproteins (LDL) in the Regulation of LDL-Cholesterol Levels
by: Sarkar, Samantha Khadija
Published: (2015)

17β-Estradiol Inhibits PCSK9-Mediated LDLR Degradation Through GPER/PLC Activation in HepG2 Cells
by: Wei Fu, et al.
Published: (2020-01-01)

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
by: Silvano Fasolato, et al.
Published: (2020-09-01)

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
by: Jean-Mathieu Berger, et al.
Published: (2017-08-01)

Patients With <italic toggle="yes">LDLR</italic> and <italic toggle="yes">PCSK9</italic> Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
by: Takahito Doi, et al.
Published: (2021-02-01)

Prevention of atherosclerosis by modulating PCSK9 expression and function
by: Samami, Samaneh
Published: (2020)

Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01)

Dégradation des membres de la famille du LDLR par la convertase PCSK9 : troisième locus de l'hypercholestérolémie familiale
by: Poirier, Steve
Published: (2011)

Dégradation des membres de la famille du LDLR par la convertase PCSK9 : troisième locus de l'hypercholestérolémie familiale
by: Poirier, Steve
Published: (2011)

Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD)
by: Dyonne Y. Vos, et al.
Published: (2021-08-01)

Naturally Occurring PCSK9 Inhibitors
by: Maria Pia Adorni, et al.
Published: (2020-05-01)

The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process – is there a link?
by: Malwina Grobelna, et al.
Published: (2019-10-01)

Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
by: Ma S, et al.
Published: (2019-08-01)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE−/− Mice
by: Ping Jin, et al.
Published: (2021-10-01)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
by: Arman Moradi, et al.
Published: (2021-02-01)

In Silico Insights into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
by: William R. Martin, et al.
Published: (2020-02-01)

The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
by: Brian T Emmer, et al.
Published: (2018-09-01)

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

PCSK9 and cancer: Rethinking the link
by: Khadijeh Mahboobnia, et al.
Published: (2021-08-01)

Rôle de PCSK9 et conséquences des chirurgies bariatriques sur le métabolisme intestinal du cholestérol
by: Moreau, François
Published: (2017)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
by: Emma M. O’Connell, et al.
Published: (2020-06-01)

Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway
by: Xin Li, et al.
Published: (2021-01-01)

Pterostilbene Increases LDL Metabolism in HL-1 Cardiomyocytes by Modulating the PCSK9/HNF1α/SREBP2/LDLR Signaling Cascade, Upregulating Epigenetic hsa-miR-335 and hsa-miR-6825, and LDL Receptor Expression
by: Yen-Kuang Lin, et al.
Published: (2021-08-01)

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
by: Jeffrey D. Browning, et al.
Published: (2010-11-01)

LDLR and ApoB are Major Genetic Causes of Autosomal Dominant Hypercholesterolemia in a Taiwanese Population
by: Kai-Chien Yang, et al.
Published: (2007-10-01)

Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-07-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9<sup>D374Y</sup> Pathway: in vitro Characterization of its Dual Hypocholesterolemic Behavior
by: Carmen Lammi, et al.
Published: (2019-07-01)